EFFECT OF SITAGLIPTIN ON GLYCEMIC CONTROL AND BEYOND - IN PATIENTS WITH TYPE 2 DIABETES MELLITUS

Ramya Ravichandar; Aravind Anapathoor Nagarajan

doi:10.22159/ajpcr.2018.v11i8.26066

Authors

Ramya Ravichandar Department of Pharmacology, Sree Balaji Medical College and Hospital, Chromepet, Chennai, Tamil Nadu, India.
Aravind Anapathoor Nagarajan Consultant Diabetologist, Rajalakshmi Diabetes Center, Kancheepuram, Tamil Nadu, India.

DOI:

https://doi.org/10.22159/ajpcr.2018.v11i8.26066

Keywords:

Diabetes mellitus, Sitagliptin, Pleiotropic, Blood pressure, Albuminuria, Lipid profile

Abstract

Objective: The objective of the study was to assess the pleiotropic effects of Sitagliptin as add-on therapy to the conventional antidiabetic drugs.

Methods: This was designed as a prospective study. 140 patients with type 2 diabetes mellitus (T2DM) whose glycated hemoglobin (HbA1c) was >7% despite receiving education on diet and exercise and/or medications were enrolled in this study. Sitagliptin (100 mg) was administered once a day orally for 6 months as an add-on therapy with the conventional antidiabetic drugs. The outcome of the therapy was assessed on the level of improvement in the fasting plasma glucose, postprandial plasma glucose, HbA1c levels, lipid profile, body mass index, blood pressure, and albuminuria in the third and 6th month when compared to the first visit.

Results: After 6 months of treatment with Sitagliptin, fasting blood glucose levels significantly reduced (202.6Â±49.21 to 186.1Â±50.14, p=0.029) as well as HbA1c (9.5Â±1.27 to 9.1Â±1.28, p=0.016). There was a statistically significant (p<0.001) reduction of blood pressure, cholesterol, and urinary albumin-creatinine ratio progressively.

Conclusion: Sitagliptin has a significant effect on lipid profile, blood pressure and albuminuria in addition to its effect on blood glucose profile and HbA1c without many side effects, in patients with T2DM.

Downloads

Download data is not yet available.

References

American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2010;33 Suppl 1:S62-9.

International Diabetes Federation. IDF Diabetes Atlas. 8th ed. Brussels, Belgium: International Diabetes Federation; 2017. Available from: http://www.diabetesatlas.org.

Anjana RM, Deepa M, Pradeepa R, Mahanta J, Narain K, Das HK, et al. Prevalence of diabetes and prediabetes in 15 states of india: Results from the ICMR-INDIAB population-based cross-sectional study. Lancet Diabetes Endocrinol 2017;5:585-96.

Mohan V, Sandeep S, Deepa R, Shah B, Varghese C. Epidemiology of type 2 diabetes: Indian scenario. Indian J Med Res 2007;125:217-30.

Cerasi E, Luft R. The plasma insulin response to glucose infusion in healthy subjects and in diabetes mellitus. Acta Endocrinol (Copenh) 1967;55:278-304.

Davis SN, Piatti PM, Monti L, Brown MD, Branch W, Hales CN, et al. Proinsulin and insulin concentrations following intravenous glucose challenges in normal, obese, and non-insulin-dependent diabetic subjects. Metabolism 1993;42:30-5.

Ahmed SJ, Masood AR, Sumana S, Ghori KA, Ansari JA, Khan M. Stroke outcomes in nondiabetic, denovo diabetic and diabetic Indian patients measured by modified Rankin scale: An observational study. Int J Pharm Pharm Sci 2017;9:94-7.

Krolewski AS, Niewczas MA, Skupien J, Gohda T, Smiles A, Eckfeldt JH, et al. Early progressive renal decline precedes the onset of microalbuminuria and its progression to macroalbuminuria. Diabetes Care 2014;37:226-34.

Kanakamani J, Ammini AC, Gupta N, Dwivedi SN. Prevalence of microalbuminuria among patients with type 2 diabetes mellitus â€“ a hospital-based study from north India. Diabetes Technol Ther 2010;12:161-6.

UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in subjects with Type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53.

Desai A, Tandon N. Management of Type 2 diabetes mellitus with oral antihyperglycaemic therapy. Natl Med J India 2007;20:192-8.

Kabul RE, Kabul E, Pratiwi A, Setiawan A, Dahlan K, Kartono A. Mathematical model of glucose-insulin system using the modified oral minimal model and the Incretin effects. Int J Pharm Pharm Sci 2015;7:451-4.

Seino Y, Fukushima M, Yabe D. GIP and GLP-1, the two incretin hormones: Similarities and differences. J Diabetes Investig 2010;1:8-23.

Ferreira L, Teixeira-de-Lemos E, Pinto F, Parada B, Mega C, Vala H, et al. Effects of Sitagliptin treatment on dysmetabolism, inflammation, and oxidative stress in an animal model of Type 2 diabetes (ZDF Rat). Mediators Inflamm 2010;2010:1-11.

Charan J, Biswas T. How to calculate sample size for different study designs in medical research? Indian J Psychol Med 2013;35:121-6.

Aschner P, Kipnes MS, Lunceford JK, Sanchez M, Mickel C, Williams- Herman DE, et al. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care 2006;29:2632-7.

Nonaka K, Kakikawa T, Sato A, Okuyama K, Fujimoto G, Kato N, et al. Efficacy and safety of sitagliptin monotherapy in japanese patients with type 2 diabetes. Diabetes Res Clin Pract 2008;79:291-8.

Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, et al. Medical management of hyperglycemia in Type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: A consensus statement of the American diabetes association and the European association for the study of diabetes. Diabetes Care 2009;32:193-203.

Singh S, Loke YK, Furberg CD. Thiazolidinediones and heart failure: A teleo-analysis. Diabetes Care 2007;30:2148-53.

Qin X, Shen H, Liu M, Yang Q, Zheng S, Sabo M, et al. GLP-1 reduces intestinal lymph flow, triglyceride absorption, and apolipoprotein production in rats. Am J Physiol Gastrointest Liver Physiol 2005;288:G943-9.

Flock G, Baggio LL, Longuet C, Drucker DJ. Incretin receptors for glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide are essential for the sustained metabolic actions of vildagliptin in mice. Diabetes 2007;56:3006-13.

Ban K, Noyan-Ashraf MH, Hoefer J, Bolz SS, Drucker DJ, Husain M, et al. Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways. Circulation 2008;117:2340-50.

Gutzwiller JP, Tschopp S, Bock A, Zehnder CE, Huber AR, Kreyenbuehl M, et al. Glucagon-like peptide 1 induces natriuresis in healthy subjects and in insulin-resistant obese men. J Clin Endocrinol Metab 2004;89:3055-61.

HorvÃ¡th EM, Benko R, Kiss L, MurÃ¡nyi M, PÃ©k T, Fekete K, et al. Rapid â€˜glycaemic swingsâ€™ induce nitrosative stress, activate poly(ADP-ribose) polymerase and impair endothelial function in a rat model of diabetes mellitus. Diabetologia 2009;52:952-61.

Ishibashi Y, Matsui T, Takeuchi M, Yamagishi S. Glucagon-like peptide-1 (GLP-1) inhibits advanced glycation end product (AGE)- induced up-regulation of VCAM-1 mRNA levels in endothelial cells by suppressing AGE receptor (RAGE) expression. Biochem Biophys Res Commun 2010;391:1405-8.

Dozier KC, Cureton EL, Kwan RO, Curran B, Sadjadi J, Victorino GP, et al. Glucagon-like peptide-1 protects mesenteric endothelium from injury during inflammation. Peptides 2009;30:1735-41.

Amori RE, Lau J, Pittas AG. Efficacy and safety of incretin therapy in Type 2 diabetes: Systematic review and meta-analysis. JAMA 2007;298:194-206.